Sign In
Buy STXS
$1.84
-0.130 (-6.60%)
At Close: Jun 03, 2026
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
06:21pm, Monday, 12'th Aug 2024
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.07 per share a year ago.
Stereotaxis Reports 2024 Second Quarter Financial Results
04:05pm, Monday, 12'th Aug 2024
ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
04:03pm, Monday, 12'th Aug 2024
Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been su
Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024
04:05pm, Monday, 22'nd Jul 2024
ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r
Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir
04:13pm, Thursday, 18'th Jul 2024
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Hom
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
08:25am, Wednesday, 29'th May 2024
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the f
Stereotaxis (STXS) Gets CE Recertification for Approved Products
11:51am, Monday, 27'th May 2024
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
01:36pm, Friday, 24'th May 2024
Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.
Stereotaxis Receives CE Mark Recertification Under EU's MDR Regulatory Framework
08:37am, Friday, 24'th May 2024
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has rec
Stereotaxis Makes A Strategic Acquisition Bolstering Its Future
04:38am, Thursday, 23'rd May 2024
Stereotaxis made a strategic acquisition of catheter company Access Point Technologies, which is expected to contribute $5 million in sales in the first 12 months after the acquisition. Access Point w
First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology
08:42am, Wednesday, 22'nd May 2024
Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy.
Stereotaxis presents innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablati
Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies
08:36am, Wednesday, 15'th May 2024
Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.
Stereotaxis, Inc. (STXS) Q1 2024 Earnings Call Transcript
07:52pm, Monday, 13'th May 2024
Stereotaxis, Inc. (NYSE:STXS ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Offic
Stereotaxis Reports 2024 First Quarter Financial Results
04:03pm, Monday, 13'th May 2024
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result
